7 completed, 5 terminated, 3 recruiting, 1 withdrawn. 16 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 7, Terminated 5, Recruiting 3, Withdrawn 1 |
| Phase 3 | 2 | Terminated 2 |
Follow etrasimod: new trials by email Literature Review of etrasimod trials Research Report on etrasimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etrasimod as Prevention of Pouchitis etrasimod, Placebo - Pouchitis | Phase 2 | Recruiting | Maia Kayal | 40 | 2026-07-01 | 2026-09-21 |
| A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis Etrasimod - Colitis, Ulcerative | Phase 2 | Recruiting | Pfizer | 24 | 2026-05-28 | 2026-10-26 |
| Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis Etrasimod, Placebo, Corticosteroids - Immune Checkpoint Inhibitor-Related Diarrhea and Colitis | Phase 2 | Withdrawn | Yale University | 2026-01-01 | 2026-01-14 | |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Etrasimod - Ulcerative Colitis | Phase 2 | Recruiting | Pfizer | 36 | 2022-12-16 | 2026-10-27 |
| Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Pfizer | 54 | 2021-09-10 | 2024-10-29 |
| Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Pfizer | 234 | 2021-04-12 | 2025-07-15 |
| A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis Etrasimod, Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Pfizer | 108 | 2020-12-15 | 2024-05-06 |
| Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata Etrasimod, Placebo - Alopecia Areata | Phase 2 | Completed | Pfizer | 80 | 2020-07-29 | 2024-06-26 |
| A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Etrasimod, Placebo - Crohn's Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 379 | 2020-01-06 | 2026-07-01 |
| A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo - Atopic Dermatitis | Phase 2 | Completed | Arena Pharmaceuticals | 140 | 2019-10-04 | 2022-11-04 |
| Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis APD334 - Primary Biliary Cholangitis | Phase 2 | Terminated | Arena Pharmaceuticals | 2 | 2017-12-29 | 2022-03-24 |
| Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations APD334 - Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations | Phase 2 | Terminated | Arena Pharmaceuticals | 1 | 2017-07-17 | 2020-12-31 |
| Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum APD334 - Pyoderma Gangrenosum | Phase 2 | Terminated | Arena Pharmaceuticals | 2 | 2017-06-07 | 2021-06-11 |
| Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Arena Pharmaceuticals | 118 | 2016-01-25 | 2021-11-26 |
| Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Arena Pharmaceuticals | 156 | 2015-10-15 | 2021-04-05 |
Colitis, Ulcerative (6) · Colitis (2) · Dermatitis, Atopic (2) · Inflammatory Bowel Diseases (2) · Alopecia (1) · Alopecia Areata (1) · Crohn Disease (1) · Eczema (1) · Eosinophilic Esophagitis (1) · Liver Cirrhosis, Biliary (1) · Pouchitis (1) · Pyoderma Gangrenosum (1) · Ulcer (1)
Pfizer (8) · Arena Pharmaceuticals (6) · Maia Kayal (1) · Yale University (1)
United States (13) · Australia (9) · Canada (8) · Germany (7) · Poland (7) · Belgium (6) · Spain (6) · Czechia (5) · France (5) · Israel (5) · Bulgaria (4) · Hungary (4) · Japan (4) · New Zealand (4) · Russia (4)
Arena CT.gov Administrator (5) · Harriet Kluger, MD (1) · Maia Kayal, MD (1)
PMID 39575597, PMID 39778975, PMID 31711921, PMID 38245818, PMID 39526078, PMID 40145547, PMID 40275818, PMID 40381637, PMID 42248437
2015 (1), 2025 (1)